{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:02:09Z","timestamp":1787662929201,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104157","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:00:05Z","timestamp":1662440405000},"page":"104157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review"],"prefix":"10.1016","volume":"68","author":[{"given":"Mohammad Ali","family":"Sahraian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1724-6432","authenticated-orcid":false,"given":"Amir Mohammad","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensiyeh","family":"Jenabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Etminani","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-8132","authenticated-orcid":false,"given":"Sara","family":"Ataei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-13-138","article-title":"Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study","volume":"13","author":"Agashivala","year":"2013","journal-title":"BMC Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104157_bib0002","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/15563650.2019.1581940","article-title":"Psoriasiform eruption caused by teriflunomide in a patient with multiple sclerosis","volume":"57","author":"Agirgol","year":"2019","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-163","article-title":"Effects of dimethyl fumarate on neuroprotection and immunomodulation","volume":"9","author":"Albrecht","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0004","article-title":"Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: an expert consensus narrative review","volume":"8","author":"Alroughani","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.104157_bib0006","article-title":"A case of presumed herpes keratouveitis in a patient treated with fingolimod","volume":"2","author":"Ayers","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2022.104157_bib0007","first-page":"413","article-title":"Effects of Vitamin D supplements on IL-10 and INF\u03b3 levels in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"14","author":"Azimi","year":"2019","journal-title":"Maedica"},{"issue":"6","key":"10.1016\/j.msard.2022.104157_bib0008","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.msard.2022.104157_bib0009","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.104157_bib0010","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104157_bib0011","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.msard.2022.104157_bib0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/1352458518761185","article-title":"Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: a case report","volume":"24","author":"Camara-Lemarroy","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40263-015-0299-y","article-title":"Teriflunomide in patients with relapsing\u2013remitting forms of multiple sclerosis","volume":"30","author":"Chan","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2022.104157_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.msard.2022.104157_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40744-016-0025-3","article-title":"Chronic diarrhea associated with high teriflunomide blood concentration","volume":"3","author":"Duquette","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.msard.2022.104157_bib0017","first-page":"2017","article-title":"Case report: ventricular tachycardia after initiation of fingolimod","author":"Elounais","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2022.104157_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101515","article-title":"Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod","volume":"38","author":"Feige","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"51","key":"10.1016\/j.msard.2022.104157_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028246","article-title":"Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: a case report","volume":"100","author":"Ferreira","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.msard.2022.104157_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102180","article-title":"Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod","volume":"42","author":"Foerch","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.104157_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104157_bib0022","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1177\/1352458515596601","article-title":"Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis","volume":"21","author":"Gerschenfeld","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104157_bib0023","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","author":"Gold","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2022.104157_bib0024","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1-2","key":"10.1016\/j.msard.2022.104157_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jns.2014.06.013","article-title":"Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy","volume":"344","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3988\/jcn.2015.11.1.9","article-title":"Oral disease-modifying therapies for multiple sclerosis","volume":"11","author":"Kim","year":"2015","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2022.104157_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836571","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment","volume":"12","author":"Klotz","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104157_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.msard.2017.07.001","article-title":"A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis","volume":"17","author":"Landais","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2022.104157_bib0029","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.wnl.0000344567.51394.e3","article-title":"Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report","volume":"72","author":"Leypoldt","year":"2009","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.104157_bib0030","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s11010-021-04119-z","article-title":"A review of possible therapies for multiple sclerosis","volume":"476","author":"Li","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.msard.2022.104157_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2016.03.009","article-title":"An unusual infection in MS patient treated with dimethyl fumarate: a case report of omphalitis","volume":"7","author":"Lorefice","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104157_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40779-020-00238-8","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Military Med. Res."},{"key":"10.1016\/j.msard.2022.104157_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.msard.2017.09.029","article-title":"Nail loss after teriflunomide treatment: a new potential adverse event","volume":"18","author":"Mancinelli","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104157_bib0034","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.msard.2018.02.015","article-title":"A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy","volume":"21","author":"Navardi","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104157_bib0035","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2018.11.020","article-title":"Palmar pustular psoriasis associated with teriflunomide treatment","volume":"27","author":"Negrotto","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104157_bib0036","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jocn.2017.10.077","article-title":"Mycosis fungoides\u2013A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis","volume":"48","author":"Nitsan","year":"2018","journal-title":"J. Clin. Neurosci."},{"issue":"14","key":"10.1016\/j.msard.2022.104157_bib0037","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2022.104157_bib0038","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O'Connor","year":"2016","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2022.104157_bib0039","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1177\/1352458516645868","article-title":"Development of a primary cutaneous CD30 (+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod","volume":"22","author":"Papathemeli","year":"2016","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2022.104157_bib0040","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/trf.15151","article-title":"The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis","volume":"59","author":"Quintanilla-Bord\u00e1s","year":"2019","journal-title":"Transfusion (Paris)"},{"issue":"17","key":"10.1016\/j.msard.2022.104157_bib0041","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2022.104157_bib0042","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1177\/1352458519900961","article-title":"Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis","volume":"26","author":"Son","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.104157_bib0043","doi-asserted-by":"crossref","DOI":"10.5812\/archneurosci.31295","article-title":"Fingolimod for multiple sclerosis; mechanism of action, safety and toxicity","volume":"3","author":"Tolou-Ghamari","year":"2016","journal-title":"Arch. Neurosci."},{"key":"10.1016\/j.msard.2022.104157_bib0044","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis\u2013a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104157_bib0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00415-011-6367-4","article-title":"Does fingolimod in multiple sclerosis patients cause macular edema?","volume":"259","author":"Turaka","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104157_bib0046","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.msard.2018.06.018","article-title":"Teeth loss after teriflunomide treatment: casual or causal? A short case series","volume":"24","author":"Vacchiano","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104157_bib0047","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/PPA.S187983","article-title":"Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain","volume":"13","author":"Verdugo","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2022.104157_bib0048","first-page":"333","article-title":"Review of teriflunomide and its potential in the treatment of multiple sclerosis","volume":"5","author":"Warnke","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2022.104157_bib0049","first-page":"987","article-title":"Life-threatening asthma attack during prolonged fingolimod treatment: case report","volume":"8","author":"Zecca","year":"2014","journal-title":"Patient Prefer. Adherence"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:06Z","timestamp":1761901686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":48,"alternative-id":["S2211034822006642"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104157","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104157"}}